Who signed the USANA (USNA) 8-K related to preliminary Q3 2025 results?

The report was signed on behalf of USANA Health Sciences, Inc. by G. Douglas Hekking, Chief Financial Officer .

USANA Health Sciences (NYSE: USNA) issues Q3 2025 preliminary results update

Q: How is the USANA (USNA) preliminary results information treated legally?

USANA states that the information is being furnished and not deemed filed under the Securities Exchange Act of 1934, which affects how it is treated for certain liability provisions.

Q: Which items of the 8-K does USANA (USNA) use for this disclosure?

USANA uses Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure) , with Item 7.01 incorporating the Item 2.02 information by reference.

Q: What exhibits are included with this USANA (USNA) 8-K?

The filing includes Exhibit 99.1 , a press release with preliminary third-quarter 2025 results, and Exhibit 104 , the cover page interactive data file embedded in the Inline XBRL document.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

USANA Health Sciences, Inc. filed a current report to let investors know it has released a press release with preliminary financial results for its third quarter ended September 27, 2025. The company is furnishing this information under the sections covering results of operations and Regulation FD, and it attaches the press release as Exhibit 99.1. The disclosure is classified as “furnished” rather than “filed,” which limits its use for certain legal purposes but still makes the preliminary quarterly results publicly available.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

10/09/2025 - 04:10 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

October 9, 2025

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction of incorporation)


001-35024			87-0500306
(Commission File No.)			(IRS Employer Identification No.)

3838 West Parkway Boulevard

Salt Lake City, Utah 84120

(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	USNA	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On October 9, 2025, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing preliminary financial results for the third quarter ended September 27, 2025. The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 7.01 Regulation FD Disclosure

The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


Exhibit No.						Description
99.1						Press release issued by USANA Health Sciences, Inc. dated October 9, 2025 (furnished herewith).

104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	USANA HEALTH SCIENCES, INC.

	By:	/s/ G. Douglas Hekking
	G. Douglas Hekking, Chief Financial Officer

Date: October 9, 2025

Source: View Original Filing on SEC EDGAR

FAQ

What did USANA (USNA) announce in this 8-K filing?

USANA Health Sciences, Inc. announced that it issued a press release with preliminary financial results for its third quarter ended September 27, 2025, and furnished that release as an exhibit.

Which period do the preliminary USANA (USNA) results cover?

The preliminary financial results described by USANA cover the third quarter ended September 27, 2025.

How is the USANA (USNA) preliminary results information treated legally?

USANA states that the information is being furnished and not deemed filed under the Securities Exchange Act of 1934, which affects how it is treated for certain liability provisions.

Which items of the 8-K does USANA (USNA) use for this disclosure?

USANA uses Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), with Item 7.01 incorporating the Item 2.02 information by reference.

What exhibits are included with this USANA (USNA) 8-K?

The filing includes Exhibit 99.1, a press release with preliminary third-quarter 2025 results, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.